Erratum: The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: A preclinical assessment (Mol Neurodegener (2016) 11 (60) DOI: 10.1186/s13024-016-0127-y);The impact of glutamine supplementation on the symptoms of ataxia-telangiectasia: A preclinical assessment

Molecular Neurodegeneration

Volumn 11, Issue 1, 2016, Pages 1-

  Chen, Jianmin ^a   Chen, Yanping ^a   Vail, Graham ^a   Chow, Heiman ^b   Zhang, Yang ^b   Louie, Lauren ^a   Li, Jiali ^a,c   Hart, Ronald P ^a   Plummer, Mark R ^a   Herrup, Karl ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

Alzheimer's disease; Ataxia telangiectasia; ATM; Glutamine

Indexed keywords

ATM PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCOSE; GLUTAMINE; HISTONE DEACETYLASE 4; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; GLUCOSE BLOOD LEVEL; NEUROPROTECTIVE AGENT;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA TELANGIECTASIA; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; IN VITRO STUDY; LIFESPAN; LONG TERM POTENTIATION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; THYMUS; WEIGHT REDUCTION; ALZHEIMER DISEASE; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE CELL;

ALZHEIMER DISEASE; ANIMALS; ATAXIA TELANGIECTASIA; BLOOD GLUCOSE; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GLUTAMINE; MICE, KNOCKOUT; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 84982144148     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-017-0151-6     Document Type: Erratum

References (55)

1. Chen J, Herrup K. Glutamine acts as a neuroprotectant against DNA damage, beta-amyloid and H2O2-induced stress. PLoS One. 2012;7(3):e33177.
2. Gatti RA, et al. The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clinical reviews in allergy & immunology. 2001;20(1):87-108.
3. Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia telangiectasia. Arch Dis Child. 2006;91(7):610-1.
4. Yang Y, Hui CW, Li J, Herrup K. The interaction of the atm genotype with inflammation and oxidative stress. PLoS One. 2014;9(1):e85863.
5. Hui CW, Herrup K. Individual cytokines modulate the neurological symptoms of ATM deficiency in a region specific manner. 2015. eNeuro in press.
6. McGrath-Morrow SA, et al. Elevated serum IL-8 levels in ataxia telangiectasia. J Pediatr. 2010;156(4):682-4. e681.
7. Shanware NP, et al. Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion. Nat Commun. 2014;5:4900.
8. Kim MH, Kim A, Yu JH, Lim JW, Kim H. Glutamine deprivation induces interleukin-8 expression in ataxia telangiectasia fibroblasts. Inflammation research: official journal of the European Histamine Research Society. 2014;63(5):347-56.
9. Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. The Quarterly journal of medicine. 1992;82(298):169-79.
10. Schubert R, Reichenbach J, Zielen S. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol. 2005;140(3):517-9.
11. Kieslich M, et al. Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age. Cerebellum. 2010;9(2):190-7.
12. Ross LJ, et al. Nutritional status of patients with ataxia-telangiectasia: a case for early and ongoing nutrition support and intervention. J Paediatr Child Health. 2015.
13. Barlow C, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996;86(1):159-71.
14. Xu Y, Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev. 1996;10(19):2401-10.
15. Romito-DiGiacomo RR, Menegay H, Cicero SA, Herrup K. Effects of Alzheimer's disease on different cortical layers: the role of intrinsic differences in Abeta susceptibility. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2007;27(32):8496-504.
16. Li J, Han YR, Plummer MR, Herrup K. Cytoplasmic ATM in neurons modulates synaptic function. Current biology: CB. 2009;19(24):2091-6.
17. Li J, et al. EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia. Nat Neurosci. 2013;16(12):1745-53.
18. Greenfield JR, et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr. 2009;89(1):106-13.
19. Tolhurst G, et al. Glutamine triggers and potentiates glucagon-like peptide-1 secretion by raising cytosolic Ca2+ and cAMP. Endocrinology. 2011;152(2):405-13.
20. Calanna S, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 2013;56(5):965-72.
21. Miles PD, Treuner K, Latronica M, Olefsky JM, Barlow C. Impaired insulin secretion in a mouse model of ataxia telangiectasia. Am J Physiol Endocrinol Metab. 2007;293(1):E70-74.
22. Volkow ND, et al. Brain glucose metabolism in adults with ataxia-telangiectasia and their asymptomatic relatives. Brain: a journal of neurology. 2014;137(Pt 6):1753-61.
23. Vail G, et al. ATM protein is located on presynaptic vesicles and its deficit leads to failures in synaptic plasticity. Journal of neurophysiology:jn. 2016;00006:02016.
24. Genik PC, et al. Strain background determines lymphoma incidence in Atm knockout mice. Neoplasia. 2014;16(2):129-36.
25. Ortinski PI, et al. Selective induction of astrocytic gliosis generates deficits in neuronal inhibition. Nat Neurosci. 2010;13(5):584-91.
26. Chen S, Wang G, Makrigiorgos GM, Price BD. Stable siRNA-mediated silencing of ATM alters the transcriptional profile of HeLa cells. Biochem Biophys Res Commun. 2004;317(4):1037-44.
27. Rotman G, Shiloh Y. ATM: a mediator of multiple responses to genotoxic stress. Oncogene. 1999;18(45):6135-44.
28. Nicklin P, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521-34.
29. Shen C, Houghton PJ. The mTOR pathway negatively controls ATM by up-regulating miRNAs. Proc Natl Acad Sci U S A. 2013;110(29):11869-74.
30. Alexander A, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A. 2010;107(9):4153-8.
31. Li J, et al. Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat Med. 2012;18(5):783-90.
32. Patterson SL, et al. Some forms of cAMP-mediated long-lasting potentiation are associated with release of BDNF and nuclear translocation of phospho-MAP kinase. Neuron. 2001;32(1):123-40.
33. Sakata K, et al. Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. Proc Natl Acad Sci U S A. 2009;106(14):5942-7.
34. Lamb BT, et al. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum Mol Genet. 1997;6(9):1535-41.
35. Herrup K, Li J, Chen J. The role of ATM and DNA damage in neurons: upstream and downstream connections. DNA repair. 2013;12(8):600-4.
36. Rozas NS, et al. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation. Biochem Biophys Res Commun. 2015;457(4):635-9.
37. Hiltunen JK, et al. Mitochondrial fatty acid synthesis and respiration. Biochim Biophys Acta. 2010;1797(6-7):1195-202.
38. Valentin-Vega YA, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012;119(6):1490-500.
39. Yang DQ, Halaby MJ, Li Y, Hibma JC, Burn P. Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration. Drug Discov Today. 2011.
40. Armata HL, et al. Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis. Mol Cell Biol. 2010;30(24):5787-94.
41. Clem BF, Chesney J. Molecular pathways: regulation of metabolism by RB. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18(22):6096-100.
42. Billups D, Marx MC, Mela I, Billups B. Inducible presynaptic glutamine transport supports glutamatergic transmission at the calyx of Held synapse. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2013;33(44):17429-34.
43. Ruzzo EK, et al. Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron. 2013;80(2):429-41.
44. Scholl-Burgi S, et al. Amino acid cerebrospinal fluid/plasma ratios in children: influence of age, gender, and antiepileptic medication. Pediatrics. 2008;121(4):e920-926.
45. Ligthart-Melis GC, et al. Glutamine is an important precursor for de novo synthesis of arginine in humans. Am J Clin Nutr. 2008;87(5):1282-9.
46. Kan MJ, et al. Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2015;35(15):5969-82.
47. Hwang SY, et al. Glucosamine exerts a neuroprotective effect via suppression of inflammation in rat brain ischemia/reperfusion injury. Glia. 2010;58(15):1881-92.
48. Son J, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101-5.
49. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427-33.
50. Parry-Billings M, et al. The effect of tumour bearing on skeletal muscle glutamine metabolism. The International journal of biochemistry. 1991;23(9):933-7.
51. Yoshida S, Kaibara A, Ishibashi N, Shirouzu K. Glutamine supplementation in cancer patients. Nutrition. 2001;17(9):766-8.
52. Yang L, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014;10:728.
53. Klimberg VS, et al. Glutamine suppresses PGE2 synthesis and breast cancer growth. J Surg Res. 1996;63(1):293-7.
54. Lim V, Korourian S, Todorova VK, Kaufmann Y, Klimberg VS. Glutamine prevents DMBA-induced squamous cell cancer. Oral Oncol. 2009;45(2):148-55.
55. Rubio I, et al. Oral glutamine reduces radiation morbidity in breast conservation surgery. JPEN J Parenter Enteral Nutr. 2013.